<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00372294</url>
  </required_header>
  <id_info>
    <org_study_id>8415</org_study_id>
    <nct_id>NCT00372294</nct_id>
  </id_info>
  <brief_title>To Compare Intravitreal Clindamycin &amp; Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shahid Beheshti University of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shahid Beheshti University of Medical Sciences</source>
  <brief_summary>
    <textblock>
      Toxoplasmosis, an intra cellular parasite, is a very important cause of chorioretinitis. The
      goal of treatment is arresting multiplication of the parasite in its inflammatory active
      phase. In this study the investigators try to compare the efficacy of the classic regimen
      (Pyrimethamine-Sulfadiazine + Prednisolon) with intravitreal Clindamycin &amp; Dexamethasone.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2005</start_date>
  <completion_date type="Anticipated">November 2008</completion_date>
  <primary_completion_date type="Anticipated">August 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <number_of_arms>2</number_of_arms>
  <condition>Chorioretinitis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Classic regimen (Pyrimethamine-Sulfadiazine + Prednisolon)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intravitreal Clindamycin &amp; Dexamethasone</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pyrimethamine-sulfadiazine + prednisolone</intervention_name>
    <description>Administration of pyrimethamine-sulfadiazine + prednisolone</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clindamycin+Dexamethasone</intervention_name>
    <description>Intravitreal injection of Clindamycin+Dexamethasone</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Toxoplasmic chorioretinitis

          -  Location of the lesion within zone I of the retina or a lesion greater than 2DD with
             3+-4+ vitreous inflammation in zone II or III

          -  No allergic history to the used drugs

          -  No any other diseases

        Exclusion Criteria:

          -  Any allergic reaction to the used medications

          -  One eyed patients

          -  Partially treated patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masoud Soheilian, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ophthalmic Research Center of Shaheed Beheshti Medical University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ophthalmic Research Center</name>
      <address>
        <city>Tehran</city>
        <zip>16666</zip>
        <country>Iran, Islamic Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Iran, Islamic Republic of</country>
  </location_countries>
  <verification_date>June 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2006</study_first_submitted>
  <study_first_submitted_qc>September 5, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 6, 2006</study_first_posted>
  <last_update_submitted>July 28, 2008</last_update_submitted>
  <last_update_submitted_qc>July 28, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">July 30, 2008</last_update_posted>
  <keyword>Toxoplasmosis</keyword>
  <keyword>Chorioretinitis</keyword>
  <keyword>Intravitreal Clindamycin</keyword>
  <keyword>Dexamethasone in chorioretinitis</keyword>
  <keyword>Toxoplasmic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chorioretinitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Prednisolone acetate</mesh_term>
    <mesh_term>Methylprednisolone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Prednisolone</mesh_term>
    <mesh_term>Methylprednisolone</mesh_term>
    <mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
    <mesh_term>Prednisolone hemisuccinate</mesh_term>
    <mesh_term>Prednisolone phosphate</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Clindamycin</mesh_term>
    <mesh_term>Clindamycin palmitate</mesh_term>
    <mesh_term>Pyrimethamine</mesh_term>
    <mesh_term>Clindamycin phosphate</mesh_term>
    <mesh_term>Sulfadiazine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

